[Techniques, indications and results of permanent prostate brachytherapy for localized prostate cancer].
Permanent seed brachytherapy as a monotherapy is an appropriate treatment in patients with low risk localized prostate cancer such as intraprostatic cancer, T1-2 stage, PSA less than 10 ng/mL, low tumour volume, well differentiated cancer (Gleason score less than 7), gland size less than 50 mL, no micturition symptoms that could decompensate after implantation. A brachytherapy program needs a specialized multidisciplinary team with the collaboration of urologists, radiotherapists (authorized person to manipulate radioactive elements), and physicists. The 10-year oncologic and morbidity results have been published in the literature and are comparable to those of other standard treatments of localized prostate cancer such as radical prostatectomy and external beam radiation therapy.
Bladou
F
F
Service d'urologie, hôpital Salvator, 249, boulevard de Sainte-Marguerite, BP51, 13274 Marseille, France. fbladou@mail.ap-hm.fr
Thuret
R
R
Gravis
G
G
Karsenty
G
G
Serment
G
G
Salem
N
N
D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods; D004307:Dose-Response Relationship, Radiation; D007172:Erectile Dysfunction / Q000209:etiology; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage; D008297:Male; D009367:Neoplasm Staging; D010348:Patient Care Team; D018579:Patient Selection; D011379:Prognosis; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D012307:Risk Factors; D013997:Time Factors; D014463:Ultrasonography
D007457:Iodine Radioisotopes; D017430:Prostate-Specific Antigen